Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

The impact of a suspicious prostate biopsy on patients' psychological, socio-behavioral, and medical care outcomes.

Fowler FJ Jr, Barry MJ, Walker-Corkery B, Caubet JF, Bates DW, Lee JM, Hauser A, McNaughton-Collins M.

J Gen Intern Med. 2006 Jul;21(7):715-21.

2.

The role of anxiety in prostate carcinoma: a structured review of the literature.

Dale W, Bilir P, Han M, Meltzer D.

Cancer. 2005 Aug 1;104(3):467-78. Review.

3.

Effects of false-positive prostate cancer screening results on subsequent prostate cancer screening behavior.

Ford ME, Havstad SL, Demers R, Cole Johnson C.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):190-4.

4.

False-positive cancer screens and health-related quality of life.

McGovern PM, Gross CR, Krueger RA, Engelhard DA, Cordes JE, Church TR.

Cancer Nurs. 2004 Sep-Oct;27(5):347-52.

PMID:
15525861
5.

Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.

Taylor KL, Shelby R, Gelmann E, McGuire C.

J Natl Cancer Inst. 2004 Jul 21;96(14):1083-94.

6.

Enthusiasm for cancer screening in the United States.

Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG.

JAMA. 2004 Jan 7;291(1):71-8.

PMID:
14709578
7.

Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.

Cohen L, Fouladi RT, Babaian RJ, Bhadkamkar VA, Parker PA, Taylor CC, Smith MA, Gritz ER, Basen-Engquist K.

Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):610-7.

8.

Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message?

Chan EC, Vernon SW, O'Donnell FT, Ahn C, Greisinger A, Aga DW.

Am J Public Health. 2003 May;93(5):779-85.

9.

Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?

Sirovich BE, Schwartz LM, Woloshin S.

JAMA. 2003 Mar 19;289(11):1414-20.

PMID:
12636464
10.

Screening for prostate cancer: recommendation and rationale.

U.S. Preventive Services Task Force.

Ann Intern Med. 2002 Dec 3;137(11):915-6. No abstract available.

PMID:
12458992
11.

Psychological benefits of prostate cancer screening: the role of reassurance.

Cantor SB, Volk RJ, Cass AR, Gilani J, Spann SJ.

Health Expect. 2002 Jun;5(2):104-13.

PMID:
12031051
12.

Validation of case-mix measures derived from self-reports of diagnoses and health.

Fan VS, Au D, Heagerty P, Deyo RA, McDonell MB, Fihn SD.

J Clin Epidemiol. 2002 Apr;55(4):371-80.

PMID:
11927205
13.

Trends and risk factors for prostate biopsy complications in the pre-PSA and PSA eras, 1980 to 1997.

Roberts RO, Bergstralh EJ, Besse JA, Lieber MM, Jacobsen SJ.

Urology. 2002 Jan;59(1):79-84.

PMID:
11796286
14.
15.

Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer.

Barry MJ.

N Engl J Med. 2001 May 3;344(18):1373-7. Review. No abstract available.

PMID:
11333995
16.

The impact of abnormal mammograms on psychosocial outcomes and subsequent screening.

Lipkus IM, Halabi S, Strigo TS, Rimer BK.

Psychooncology. 2000 Sep-Oct;9(5):402-10.

PMID:
11038478
17.

False-positive findings in mammography screening induces short-term distress - breast cancer-specific concern prevails longer.

Aro AR, Pilvikki Absetz S, van Elderen TM, van der Ploeg E, van der Kamp LJ.

Eur J Cancer. 2000 Jun;36(9):1089-97.

PMID:
10854941
18.
19.

The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.

Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH.

Med Care. 1998 Jul;36(7):1002-12.

PMID:
9674618
20.

Short-term effects of population-based screening for prostate cancer on health-related quality of life.

Essink-Bot ML, de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schröder FH.

J Natl Cancer Inst. 1998 Jun 17;90(12):925-31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk